Emer­gent lands an­oth­er big mon­ey con­tract from BAR­DA for an­thrax

Af­ter neg­a­tive feed­back from the FDA, the loss of busi­ness with As­traZeneca and the dis­rup­tion to the Covid-19 sup­ply chain, the US gov­ern­ment has not lost faith in Emer­gent BioSo­lu­tions.

Emer­gent has land­ed a con­tract worth near­ly $400 mil­lion from BAR­DA to man­u­fac­ture its an­thrax vac­cine for the na­tion­al stock­pile for the next 18 months.

The news was re­vealed as a part of the com­pa­ny’s Form 8-K fil­ing with the SEC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER